Covered recipient · General Payments record
HILLARY E NORTON
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$295,538.93
370 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $172,675.00 | 71 |
| Consulting Fee | $56,413.50 | 18 |
| Travel and Lodging | $45,192.03 | 124 |
| Honoraria | $14,175.00 | 4 |
| Food and Beverage | $6,866.05 | 150 |
| Education | $217.35 | 3 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $132,009.83 | 147 |
| UCB, Inc. | $53,692.10 | 72 |
| PFIZER INC. | $25,581.26 | 19 |
| Horizon Therapeutics plc | $16,675.23 | 19 |
| Lilly USA, LLC | $14,580.10 | 18 |
| Janssen Biotech, Inc. | $14,332.62 | 17 |
| Amgen Inc. | $13,862.07 | 29 |
| AstraZeneca Pharmaceuticals LP | $8,169.69 | 23 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $7,009.50 | 14 |
| Averitas Pharma Inc. | $5,377.56 | 4 |
| Janssen Scientific Affairs, LLC | $3,500.00 | 1 |
| UCB SA | $570.00 | 1 |
| Arcutis Biotherapeutics, Inc. | $51.89 | 1 |
| TerSera Therapeutics LLC | $49.74 | 2 |
| GlaxoSmithKline, LLC. | $46.54 | 2 |
| Organon LLC | $30.80 | 1 |
Page 2 of 8; records 51–100 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HILLARY E NORTON
NPI 1093911323 · CMS profile ID 366074
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
SANTA FE, NM
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 8; records 51–100 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1093911323?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HILLARY E NORTON, NPI 1093911323, CMS profile ID 366074. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093911323?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). HILLARY E NORTON, NPI 1093911323, CMS profile ID 366074. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093911323?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- HILLARY E NORTON, NPI 1093911323, CMS profile ID 366074, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 8; records 51–100 of 370 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1093911323?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
370 matching records · $295,538.93 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 370.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| UCB, Inc. | $50.00 | 10/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021545491 | CMS |
| UCB, Inc. | $48.60 | 10/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155525720 | CMS |
| UCB, Inc. | $196.08 | 10/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155525722 | CMS |
| UCB, Inc. | $247.55 | 10/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155525724 | CMS |
| UCB, Inc. | $252.55 | 10/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155525726 | CMS |
| UCB, Inc. | $461.80 | 10/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155525728 | CMS |
| Amgen Inc. | $8.17 | 10/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019928209 | CMS |
| ABBVIE INC. | $3,600.00 | 10/25/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022451 | CMS |
| Novartis Pharmaceuticals Corporation | $6.62 | 10/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992734645 | CMS |
| Novartis Pharmaceuticals Corporation | $3.25 | 10/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992734649 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.64 | 10/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011558691 | CMS |
| ABBVIE INC. | $750.00 | 10/20/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022447 | CMS |
| ABBVIE INC. | $750.00 | 10/20/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022449 | CMS |
| ABBVIE INC. | $18.79 | 10/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022445 | CMS |
| ABBVIE INC. | $4,200.00 | 10/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022443 | CMS |
| ABBVIE INC. | $3,000.00 | 10/16/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022439 | CMS |
| ABBVIE INC. | $3,000.00 | 10/16/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022441 | CMS |
| Amgen Inc. | $5.73 | 10/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020588067 | CMS |
| ABBVIE INC. | $10.45 | 10/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022437 | CMS |
| ABBVIE INC. | $8.91 | 10/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022431 | CMS |
| ABBVIE INC. | $1,646.40 | 10/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022433 | CMS |
| ABBVIE INC. | $267.16 | 10/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022435 | CMS |
| ABBVIE INC. | $57.44 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022417 | CMS |
| ABBVIE INC. | $36.00 | 10/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022419 | CMS |
| ABBVIE INC. | $100.04 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022421 | CMS |
| ABBVIE INC. | $331.58 | 10/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022423 | CMS |
| ABBVIE INC. | $461.46 | 10/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022425 | CMS |
| ABBVIE INC. | $27.75 | 10/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022427 | CMS |
| ABBVIE INC. | $218.59 | 10/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022429 | CMS |
| ABBVIE INC. | $320.96 | 10/09/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022413 | CMS |
| ABBVIE INC. | $147.90 | 10/09/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022415 | CMS |
| AstraZeneca Pharmaceuticals LP | $28.69 | 10/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011727539 | CMS |
| UCB, Inc. | $8,550.00 | 10/09/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021530253 | CMS |
| Horizon Therapeutics plc | $16.52 | 10/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987052977 | CMS |
| ABBVIE INC. | $460.71 | 10/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022405 | CMS |
| ABBVIE INC. | $130.00 | 10/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022407 | CMS |
| ABBVIE INC. | $344.13 | 10/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022409 | CMS |
| ABBVIE INC. | $136.00 | 10/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022411 | CMS |
| ABBVIE INC. | $156.00 | 10/02/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998022403 | CMS |
| Averitas Pharma Inc. | $4,500.00 | 09/27/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054314429 | CMS |
| Averitas Pharma Inc. | $372.55 | 09/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054314437 | CMS |
| Averitas Pharma Inc. | $299.45 | 09/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054314447 | CMS |
| Averitas Pharma Inc. | $205.56 | 09/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1054314453 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.04 | 09/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014385445 | CMS |
| UCB, Inc. | $1,150.00 | 09/26/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021545653 | CMS |
| Amgen Inc. | $10.86 | 09/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1019928243 | CMS |
| UCB, Inc. | $13.22 | 09/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021545391 | CMS |
| UCB, Inc. | $13.22 | 09/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021545397 | CMS |
| UCB, Inc. | $50.00 | 09/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021545473 | CMS |
| UCB, Inc. | $50.00 | 09/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021545479 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $17,365.77 | 4 |
| PY2025 | Principal investigator | $1,111,623.00 | 42 |
| PY2024 | Recipient | $2,820.02 | 2 |
| PY2024 | Principal investigator | $1,278,725.00 | 17 |
| PY2023 | Recipient | $3,200.00 | 1 |
| PY2023 | Principal investigator | $199,743.62 | 13 |
| PY2022 | Recipient | $3,699.00 | 4 |
| PY2022 | Principal investigator | $67,946.96 | 6 |
| PY2021 | Principal investigator | $124,878.06 | 9 |
| PY2020 | Recipient | $1,575.00 | 1 |
| PY2020 | Principal investigator | $210,123.70 | 20 |
| PY2019 | Recipient | $24,721.00 | 1 |
| PY2019 | Principal investigator | $235,790.61 | 15 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
46 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,965.10 | 12/22/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093561 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,024.60 | 12/17/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289780 |
| Principal investigator 1 | ABBVIE INC. | $8,583.80 | 12/04/2025 | Non-covered Recipient Entity HILLARY E NORTON MD PC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202528392 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $133.97 | 12/02/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093548 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $46.20 | 12/01/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288869 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $268.00 | 12/01/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288885 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,135.60 | 11/21/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288649 |
| Principal investigator 1 | ABBVIE INC. | $902.20 | 11/05/2025 | Non-covered Recipient Entity HILLARY E NORTON MD PC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202521339 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $188.93 | 10/20/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093516 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,274.80 | 10/20/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093521 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,707.63 | 10/09/2025 | Non-covered Recipient Entity INSPIRE SANTA FE MEDICAL GROUP | An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) | No dispute reported | 06/30/2026 | 1190305333 |
| Principal investigator 1 | ABBVIE INC. | $5,349.00 | 10/08/2025 | Non-covered Recipient Entity HILLARY E NORTON MD PC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202513551 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,150.00 | 10/08/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286521 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,440.00 | 10/08/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286523 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,790.00 | 10/03/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286325 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500.00 | 10/03/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286327 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,070.21 | 09/15/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093493 |
| Principal investigator 1 | ABBVIE INC. | $8,100.00 | 09/04/2025 | Non-covered Recipient Entity HILLARY E NORTON MD PC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202509100 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,604.30 | 09/03/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093499 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $135.00 | 08/18/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093469 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $410.00 | 08/18/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226093475 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $40.00 | 08/18/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226093482 |
| Principal investigator 1 | Amgen Inc. | $893.86 | 07/28/2025 | Non-covered Recipient Entity INSPIRE SANTA FE MEDICAL GROUP | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246642744 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,937.40 | 07/28/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093462 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $200.53 | 07/21/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093456 |
| Recipient | SANOFI US SERVICES INC. | $262.82 | 07/02/2025 | Covered Recipient Physician | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226123803 |
| Recipient | SANOFI US SERVICES INC. | $7,786.80 | 07/02/2025 | Covered Recipient Physician | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226123807 |
| Recipient | SANOFI US SERVICES INC. | $8,879.00 | 07/02/2025 | Covered Recipient Physician | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226123810 |
| Principal investigator 1 | Eli Lilly and Company | $163.55 | 05/08/2025 | Non-covered Recipient Entity DERMATOLOGY CENTE FOR SKIN HEALTH | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187879843 |
| Principal investigator 1 | Amgen Inc. | $62,087.98 | 04/17/2025 | Non-covered Recipient Entity INTERSPOND LLC | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246642950 |
| Principal investigator 1 | Amgen Inc. | $24,031.72 | 04/17/2025 | Non-covered Recipient Entity INTERSPOND LLC | P4 Uncontrolled Gout FORWARD II | No dispute reported | 06/30/2026 | 1246642958 |
| Principal investigator 1 | Amgen Inc. | $184,457.76 | 04/15/2025 | Non-covered Recipient Entity INSPIRE SANTA FE MEDICAL GROUP | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246642752 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,755.70 | 04/14/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226093438 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,500.00 | 04/07/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093375 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,600.00 | 04/02/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226093369 |
| Recipient | Eli Lilly and Company | $437.15 | 03/25/2025 | Covered Recipient Physician | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187870985 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,575.00 | 02/18/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1226093380 |
| Principal investigator 1 | Eli Lilly and Company | $5,965.08 | 02/11/2025 | Non-covered Recipient Entity CAMC HEALTH EDUCATION AND RESEARCH INSTITUTE INC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187878251 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,500.00 | 02/04/2025 | Non-covered Recipient Entity HILLARY E NORTON MD | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol | No dispute reported | 06/30/2026 | 1190309052 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,749.39 | 01/21/2025 | Non-covered Recipient Entity Hillary E Norton Md Pc Inspire Santa Fe Medical Group | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226093393 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $16,000.00 | 01/17/2025 | Non-covered Recipient Entity HILLARY E NORTON MD | An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) | No dispute reported | 06/30/2026 | 1190309054 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,758.99 | 01/15/2025 | Non-covered Recipient Entity INSPIRE SANTA FE MEDICAL GROUP | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol | No dispute reported | 06/30/2026 | 1190305331 |
| Principal investigator 1 | Amgen Inc. | $640,558.80 | 01/14/2025 | Non-covered Recipient Entity INSPIRE SANTA FE MEDICAL GROUP | A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants | No dispute reported | 06/30/2026 | 1246642748 |
| Principal investigator 1 | Eli Lilly and Company | $22,747.00 | 01/13/2025 | Non-covered Recipient Entity INTERSPOND LLC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187882088 |
| Principal investigator 1 | Eli Lilly and Company | $84.90 | 01/09/2025 | Non-covered Recipient Entity INTERSPOND LLC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187882440 |
| Principal investigator 1 | Eli Lilly and Company | $13,236.00 | 01/06/2025 | Non-covered Recipient Entity HILLARY E. NORTON MD PC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187882490 |